Want to see GHRS full AI Analyst Report?
GHRS Stock Chart & Stats
$28.92
$0.89(3.26%)
At close: 4:00 PM EDT
$28.92
$0.89(3.26%)
Day’s Range― - ―
52-Week Range$12.04 - $31.44
Previous CloseN/A
Volume195.94K
Average Volume (3M)327.69K
Market Cap
$1.48B
Enterprise Value$1.43B
Total Cash (Recent Filing)$362.65M
Total Debt (Recent Filing)$360.00K
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 05, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding68,642,290
10 Day Avg. Volume337,247
30 Day Avg. Volume327,691
Financial Highlights & Ratios
PEG Ratio-3.01
Price to Book (P/B)2.77
Price to Sales (P/S)0.00
P/FCF Ratio-17.75
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.32K
Enterprise Value/Ebitda-23.11
Forecast
1Y Price Target
$43.38Price Target Upside49.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageGH Research carries essentially no debt, preserving financial flexibility while it funds clinical development. The absence of meaningful leverage limits mandatory financing costs and reduces refinancing pressure, allowing management to direct available capital toward research and trials.
Substantial Equity BaseA large and recently growing equity base provides resources to continue investing in the pipeline despite the lack of commercial revenue. This capital cushion can support ongoing development activities and gives the company more time to pursue regulatory and clinical milestones.
Focused Clinical PipelineThe company has a clearly defined development focus around rapid-acting therapies for psychiatric and neurological disorders, with GH001 advancing through clinical testing. Concentrating resources on a lead program can support disciplined execution toward potential regulatory approval and commercialization.
Bears Say
Pre-revenue Business ModelGH Research has not yet demonstrated commercial revenue, so its business model currently depends on advancing clinical programs rather than selling approved products. Until commercialization occurs, financial performance remains disconnected from product demand and highly dependent on development progress.
Widening Net LossesLosses have expanded materially as research and operating expenses rise ahead of commercialization. This pattern indicates an accelerating cost base without offsetting product revenue, which can pressure shareholder capital and increase the funding required to reach future clinical and regulatory milestones.
Persistent Cash BurnSustained negative operating and free cash flow means GH Research consumes cash to fund its development activities rather than generating internal funding. Continued burn can reduce financial flexibility over time and make future progress increasingly reliant on the existing balance sheet or additional capital.
GH Research News
GHRS FAQ
What was GH Research’s price range in the past 12 months?
GH Research lowest stock price was $12.04 and its highest was $31.44 in the past 12 months.
What is GH Research’s market cap?
GH Research’s market cap is $1.48B.
When is GH Research’s upcoming earnings report date?
GH Research’s upcoming earnings report date is Nov 05, 2026 which is in 6 days.
How were GH Research’s earnings last quarter?
GH Research released its earnings results on Aug 06, 2026. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.304 by $0.074.
Is GH Research overvalued?
According to Wall Street analysts GH Research’s price is currently Undervalued.
Does GH Research pay dividends?
GH Research does not currently pay dividends.
What is GH Research’s EPS estimate?
GH Research’s EPS estimate is -0.31.
How many shares outstanding does GH Research have?
GH Research has 68,642,290 shares outstanding.
What happened to GH Research’s price movement after its last earnings report?
GH Research reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.304. Following the earnings report the stock price went up 5.184%.
Which hedge fund is a major shareholder of GH Research?
Currently, no hedge funds are holding shares in GHRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GH Research Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.38 (49.98% Upside)
$43.38 (49.98% Upside)
Blogger Sentiment
Bullish
GHRS Sentiment 100%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 39.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
47.92%
12-Months-Change
Fundamentals
Return on Equity
-20.86%
Trailing 12-Months
Asset Growth
18.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GH Research
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
GHRS Stock 12 Month Forecast
Average Price Target
$43.38
▲(49.98% Upside)
Technical Analysis
COMPASS Pathways
―
Bright Minds Biosciences
―
Alto Neuroscience, Inc.
―
LB Pharmaceuticals, Inc.
―
Seaport Therapeutics, Inc.
―
Ownership Overview
―
Insiders
4.78% Mutual Funds
0.08% Other Institutional Investors
94.15% Public Companies and
Individual Investors